Cooley advised Geron, while Latham & Watkins represented the underwriters in the offering. Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, has announced the pricing...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here